Latest News From Lumira Ventures

Aurinia Closes $191.7M Public Offering of Common Shares

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, …

Aurinia Prices US$166.7M Public Offering of Common Shares

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165 common shares (the “Offering”). …

Aurinia Demonstrates Voclosporin’s Superiority over Standard-of-Care in Lupus Nephritis

Jennifer Schram Aurinia Pharmaceuticals, Main Page, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced positive efficacy and safety results from its pivotal …

Bright Angel Therapeutics Announces New Funding to Advance Therapies for Invasive Fungal Infections

Jennifer Schram Bright Angel Therapeutics, Lumira News, Portfolio News, Press Release

TORONTO – Bright Angel Therapeutics, a biotechnology company focused on developing novel antifungal drugs, today announced an extension to their seed financing round, adding funding that will enable continued advancement of their lead program targeting invasive and drug-resistant fungal infections. …

Endotronix Presents Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System

Jennifer Schram Endotronix, Portfolio News, Press Release

LISLE, Ill., Nov. 18, 2019 /PRNewswire/ — Endotronix Inc., a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor). Data …